<DOC>
	<DOCNO>NCT01817400</DOCNO>
	<brief_summary>The study seek understand overweight obese make woman less fertile . The study investigator do far indicate hormone substance produce fat go blood reduces reproductive hormone woman overweight obese . The present study try find promising substance study small number woman try remove substance cause problem . Hypothesis : A circulating factor factor , either hormonal , inflammatory metabolic , cause relative pituitary hypofunction correction reproductive deficit allow obese woman infertility fail reduce body weight normal conceive , may also prevent horizontal passage adverse metabolic phenotype offspring .</brief_summary>
	<brief_title>Mediators Abnormal Reproductive Function Obesity ( MARO )</brief_title>
	<detailed_description>Specific Aim 1 : To determine whether aromatase activity measurable adipose tissue use 'compound ' ( see appendix ) precursor whether aromatase decrease adipose tissue obese woman , whether varies regional fat location . The investigator accomplish examine precursor/product ratio hormone infuse microdialysis use 'compound ' substrate . Hypothesis specific aim 1 : Aromatase activity measurable adipose tissue use testosterone precursor . Estradiol , estrone production androgen precursor decrease obese woman relative normal weight . Specific Aim 2 : To determine whether nonspecific , systemic suppression inflammation lead improve reproductive hormonal profile luteinizing hormone ( LH ) , follicle stimulate hormone ( FSH ) , Estrone conjugate ( E1c ) pregnandiol glucuronide ( Pdg ) obese woman undergo two menstrual cycle study : one treatment one treatment . This aim shall accomplish perform daily urinary hormone monitoring two menstrual cycle , one prior one treatment low-dose aspirin polyunsaturated fatty acid ( PUFAs ) . Hypothesis specific aim 2 : A nonspecific , systemic inflammatory suppression therapy result improve urinary profile LH , FSH , E1c Pdg . Specific Aim 3 : To determine whether 4 week reduction circulate insulin result improve reproductive hormonal profile LH , FSH , Estrone conjugate ( E1c ) pregnandiol glucuronide ( Pdg ) obese woman undergo two menstrual cycle study : one treatment one treatment . This aim shall accomplish perform daily urinary hormone monitoring two menstrual cycle , one prior one treatment pioglitazone . Hypothesis specific aim 3 : Chronic lower insulin pioglitazone treatment obese woman result improved urinary profile LH , FSH , E1c Pdg .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Women age 1839* meet follow criterion enrol : *Women age 4060 enrol Group A BMI least 30 kg/m2 ( Groups B C ) No history chronic disease affect hormone production , metabolism clearance No use medication know alter interact reproductive hormone insulin metabolism ( e.g . thiazolidinediones , metformin ) No use reproductive hormone within 3 month enrollment No medical condition know affect urinary hormone excretion may interfere urinary hormone measurement ( Groups B C ) No history active bladder cancer ( Group C , since pioglitazone contraindicate individual bladder cancer ) Normal prolactin thyroid stimulate hormone level screen History regular menstrual cycle every 2540 day Use reliable method contraception ( female male partner sterilization ; intrauterine device ( IUD ) ; abstinence ; diaphragm ) Hemoglobin A1c &lt; 6 % Women age 1839* meet follow criterion enrol : *Women age 4060 enrol Group A BMI least 30 kg/m2 ( Groups B C ) No history chronic disease affect hormone production , metabolism clearance No use medication know alter interact reproductive hormone insulin metabolism ( e.g . thiazolidinediones , metformin ) No use reproductive hormone within 3 month enrollment No medical condition know affect urinary hormone excretion may interfere urinary hormone measurement ( Groups B C ) No history active bladder cancer ( Group C , since pioglitazone contraindicate individual bladder cancer ) Normal prolactin thyroid stimulate hormone level screen History regular menstrual cycle every 2540 day Use reliable method contraception ( female male partner sterilization ; IUD ; abstinence ; diaphragm ) Hemoglobin A1c &lt; 6 %</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>